Status:
UNKNOWN
Analysis of Intestinal Microflora Combined With DNA Methylation in Stool to Detect Colorectal Cancer
Lead Sponsor:
WEIDONG LIU，MD
Collaborating Sponsors:
Natural Science Foundation of Hunan Province
Conditions:
Gastrointestinal Microbiome
DNA Methylation
Eligibility:
All Genders
18-75 years
Brief Summary
Introduction: Colorectal cancer (CRC) has the third highest incidence rate and the fourth mortality rate in the world. Traditional colonoscopy as an invasive examination method cannot be widely used i...
Detailed Description
Introduction： Colorectal cancer (CRC) has the third highest incidence rate and the fourth mortality rate in the world. In China, CRC is the fifth leading cause of cancer deaths. Age-standardized incid...
Eligibility Criteria
Inclusion
- colonoscopy revealing colon or rectal tumor and biopsy-confirmed adenocarcinoma or adenoma.
- no chemotherapy or surgery, and no history of other cancer.
- must be able to understand and be willing to sign informed consent.
- Healthy controls don't have tumors and history of cancer.
Exclusion
- Those who not willing to provide specimens or answer questionnaires before the study began.
- People whose stool samples does not meet the requirements.
- People who are unwilling to sign written informed consent or follow a research protocol.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04302363
Start Date
February 1 2018
End Date
December 1 2021
Last Update
March 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiangya Hospital of Central South University
Changsha, Hunan, China, 410000